Carbamazepine in osteoarthritis treatment: A novel approach targeting Nav1.7 channels

doi:10.5312/wjo.v15.i6.602

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (939)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

685

Sum=724

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

123

Sum=167

Jun 18, 2024 (publication date) through Nov 24, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Orthopedics

ISSN

2218-5836

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Orthop. Jun 18, 2024; 15(6): 602-604
Published online Jun 18, 2024. doi: 10.5312/wjo.v15.i6.602

Carbamazepine in osteoarthritis treatment: A novel approach targeting Nav1.7 channels

Rayyan Vaid, Afra Sohail, Nabiha Amir

Rayyan Vaid, Afra Sohail, Nabiha Amir, Department of Medicine, Karachi Medical and Dental College, Karachi 75500, Pakistan

Author contributions: Vaid R contributed to project administration, supervision, reviewing; Vaid R, Sohail A, and Amir N writing and editing.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Rayyan Vaid, MBBS, Academic Fellow, Academic Research, Department of Medicine, Karachi Medical and Dental College, Lane 10, Karachi 75500, Pakistan. rayyanvaid222@gmail.com

Received: March 14, 2024
Revised: May 2, 2024
Accepted: May 22, 2024
Published online: June 18, 2024
Processing time: 90 Days and 14.4 Hours

Core Tip

Core Tip: Carbamazepine, a non-specific voltage-gated sodium channel blocker primarily used for epilepsy, has shown promising results in preclinical studies for treating osteoarthritis (OA). By targeting Nav1.7 channels, it not only reduces pain but also protects against joint degradation by modulating chondrocyte biology. However, further research is needed to confirm its efficacy in humans, potentially paving the way for innovative OA treatments beyond traditional analgesics.